一个按需的变形驱动用于低速,血液相容的pVADs
Xiaolong Chen1, Zhenyan Zhu1, Yanxi Chen1
1School of Mechanical Engineering, Tongji University, Shanghai, China.
Advanced healthcare materials
|February 24, 2026
概括
一种新型的变形灵活螺旋 (MFP) 在导管输送后膨胀,改善血液流动并降低急性心脏性休克患者的血液溶解风险. 这项创新提高了皮肤穿透室腔辅助装置 (pVAD) 的安全性和效率.
科学领域:
- 生物医学工程 生物医学工程
- 心血管器械 心血管器械
- 医学创新 医学创新
背景情况:
- 穿皮室内辅助器件 (pVADs) 在急性心脏性休克中至关重要.
- 目前的pVAD面临的局限性是由于小腿部接入的输送配置文件,限制螺旋尺寸和增加血液溶解风险.
- 这需要更高的旋转速度,从而损害了设备的安全性和效率.
研究的目的:
- 引入Morphing灵活驱动 (MFP),一种旨在克服大小性能权衡的新型pVAD.
- 为了证明MFP能够从导管可输送的尺寸过渡到更大,更高效的抽配置在现场.
- 与现有技术相比,评估MFP的血液动力学性能和血液溶解风险.
主要方法:
- 开发一个集成的可部署连接系统的MFP,使其能够在现场进行变形.
- 使用计算流体动力学 (CFD) 来分析剪切应力和流动模式.
- 在匹配的血液动力学条件下进行体外实验以评估血液溶解指数.
主要成果:
- 多功率机成功地从7毫米到16毫米直径配置过渡.
- 在每分钟4000转时达到临床相关的压力梯度为10 mmHg,速度低于典型的微轴.
- CFD分析表明切割应力大多低于血液溶解值,而体外试验显示血液溶解指数与Impella CP.相似.
结论:
- 变形驱动器策略有效地将输送大小与pVAD中的动能力分开.
- 多种药物表现出一种有前途的方法,用于更安全,更有效的最小侵入性循环支持.
- 这项技术有可能显著改善急性心脏性休克患者的治疗结果.
相关概念视频
01:30ATP Driven Pumps III: V-type Pumps
V-type pumps are ATP-driven pumps found in the vacuolar membranes of plants, yeast, endosomal and lysosomal membranes of animal cells, plasma membranes of a few specialized eukaryotic cells, and some prokaryotes. They are also known as the V1Vo-ATPase, that couple ATP hydrolysis to transport protons against a concentration gradient.
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...